title: CD4+ TCR alpha beta+ T-cells developing after allogeneic bone marrow transplantation in patients with chronic myelogenous leukaemia. Dipyridamole inhibits functionally heterogeneous T-cell clones.
abstract: Dipyridamole inhibited the proliferation of functionally heterogeneous CD4+ TCR alpha beta+ T-cell clones prepared from CML-patients 4-6 weeks after allogeneic bone marrow transplantation. The effect was seen when testing concentrations corresponding to the therapeutic serum level. Dipyridamole caused a dose-dependent inhibition of PHA-stimulated proliferation both for clones dependent on exogenous IL2 and clones undergoing autocrine proliferation. The inhibition was seen when using different accessory cells (PBM or BCL), and also when dipyridamole was present during IL2- or IL4-dependent proliferation of activated T-cells. The effect of dipyridamole was also investigated for 76 T-cell clones (76 CD4+ and 7 CD8+ clones) prepared by different cloning procedures from three patients. Although these clones were heterogeneous with regard to cytotoxic function, lymphokine production or lymphokine responsiveness, dipyridamole inhibited IL2-dependent proliferation of all clones. In addition dipyridamole inhibited proliferation of CML cells.
authors.affiliation: Second Department of Internal Medicine, Tübingen University Medical Clinic, F.R.G.
authors.forename: O
authors.initials: O
authors.lastname: Bruserud
authors.forename: W
authors.initials: W
authors.lastname: Hamann
authors.forename: S
authors.initials: S
authors.lastname: Patel
authors.forename: G
authors.initials: G
authors.lastname: Pawelec
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation / Q000276:immunology*; D015704:CD4 Antigens; D002999:Clone Cells / Q000187:drug effects / Q000276:immunology; D004176:Dipyridamole / Q000494:pharmacology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D015847:Interleukin-4 / Q000494:pharmacology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000276:immunology* / Q000601:surgery; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D016693:Receptors, Antigen, T-Cell, alpha-beta; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology
chemical_list: D015704:CD4 Antigens; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D016693:Receptors, Antigen, T-Cell, alpha-beta; D015847:Interleukin-4; D004176:Dipyridamole